ArticleBMJ open respiratory research2026
Community pharmacy and lung cancer: a service innovation pilot using community pharmacy across Leeds to signpost patients with symptoms of possible lung cancers towards a patient self-request chest X-ray service.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurvival rates from lung cancer in the UK are inferior to those experienced in other high-income countries. Improving access to investigations for people with symptoms may offer some utility to address this. This pilot investigated the potential of community pharmacy to identify and signpost people with symptoms of possible lung cancer towards an existing self-request chest X-ray service (SRCXRS) in Leeds.
methodsAll community pharmacies across Leeds were invited to participate in this pilot. 27 completed necessary staff training and signposted people with symptoms of possible lung cancer towards the SRCXRS between March and September 2024. Eligibility was assessed using the existing SRCXRS criteria. Limited non-identifiable data were captured regarding the basic demographics, symptoms and medication history of people signposted. People who were signposted were provided with a unique numbered card to facilitate analysis of attendance data. Pharmacy data were used in conjunction with routinely collected attendance data from the SRCXRS.
results491 people were signposted by community pharmacies (2.83 patients/pharmacy/month). 32 people signposted attended the SRCXRS. All fulfilled the eligibility criteria to receive a chest X-ray. Nine attended with the unique number card. There was no clear evidence of difference in likelihood to attend based on Index of Multiple Deprivation (IMD) status (IMD 1-5=6.06% vs IMD 6-10=6.92%, relative risk=0.88 p=0.7) or age (p=0.42). Route to attendance data was not collected in 34.9% (n=235) of all attendees of the SRCXR during the pilot period.
conclusionThis pilot demonstrates that pharmacies were able to successfully identify and signpost people with symptoms of possible lung cancer. Results indicate that using community pharmacies in this capacity did not impact the likelihood of signposted patients to attend the SRCXRS based on age or IMD status. The reported outcomes are limited by a significant proportion of incomplete data regarding patients' route to attendance at the SRCXRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.